by Rod Raynovich | Jun 8, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Stocks Down for Sixth Straight Session: Biotechs still up Over 10% YTD As we wind down from ASCO news with few catalysts ahead, investors and traders will regroup and rebalance their portfolios. The NASDAQ index is down 21 pts off 0.77% and component biotech stocks...
by Rod Raynovich | Jun 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biopharmaceutical stocks got a boost today from a rally in NASDAQ stocks and some positive news on cancer drugs from ASCO. The IBB ($106.36) was up 1.6% off its YTD and all time high of $110 and a nice rally after five days of weakness.The XBI was also up 1.97%. Many...
by Rod Raynovich | Jun 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Speculation in small cap biopharmaceutical stocks has peaked and we urged weeks ago to raise cash positions to 10-15%. The ASCO “sell on the news effect” has continued today with some high fliers off significantly: Exelixis (EXEL $8.95) is off 18% after...
by Rod Raynovich | Jun 3, 2011 | BIOgraph, Macro
Even the Market is Bored with Economic Data-It’s All About Jobs Weak U.S. payrolls data with a rise of only 54,000 jobs push jobless rate up to 9.1% reversing April’s advance. This mirrors recent coolness in the economy and retail store data. The bond...
by Rod Raynovich | Jun 1, 2011 | BIOgraph, Macro
Market Sell-Off Over 2%-Worse Day Since August 2010 Yesterday’s rally was obviously a good hangover from your Memorial Day weekend. The bad economic news has finally come to roost and the selling today is ominous because it is the first day of the month. Over...
by Rod Raynovich | May 31, 2011 | BIOgraph
Despite the continuing gloomy backdrop of a Greece default, U.S, debt ceiling and weak housing data, several market sectors rallied today. The NASDAQ was the leader up 1.37% and the S&P was up 1.06%. Energy was the sector leader up 1.39% helped by higher crude...
by Rod Raynovich | May 31, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The life science market continued to show resilience today with a few big movers and a bidding up of large cap drugs such as Johnson and Johnson (JNJ $67.15), Novartis (NVS $64.24), Pfizer(PFE $21.21) and Sanofi-Aventis (SNY $39.42). Foreign drug companies fared...
by Rod Raynovich | May 27, 2011 | BIOgraph
This is a continuation of pre-ASCO coverage, reviewing companies that will have significant clinical presentations on cancer products in their pipeline. Incyte Corporation (INCY $17.82) up 1.94%. is focused on small molecule drugs for hematological and oncology...
by Rod Raynovich | May 27, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Our recent article on biotech investing and ETF’s in general are posted on Investor Uprising. Note to get the article on the right side of the page you need to register at no charge for Investor Uprising. Investor Uprising – IU Education – Guide to...
by Rod Raynovich | May 26, 2011 | BIOgraph
Here is a brief review of stocks to watch with potential ASCO impact although it is likely that prices already reflect the scientific news: Ariad Pharmaceuticals Inc. (ARIA $8.43) up 0.36% will present Phase III data on ponatinab, its investigational pan-BCR-ABL and...
